These siliconized vials are designed to protect sensitive, aggressive, and viscous drug products by reducing interactions with the glass and preserving the integrity of the contents. Available in both clear and amber glass, and in sizes ranging from 3ml to 500ml, these vials are suitable for various drug delivery methods, including parenteral, oral, and nasal administration.
SGD Pharma will also unveil an expansion to its Sterinity range, which includes ready-to-use (RTU) Type I and Type II moulded glass vials. With growing demand for biologics and specialty drugs, the company says RTU packaging is becoming increasingly important.
Olivier Rousseau, CEO, SGD Pharma, said: “At CPHI 2024 we are showcasing solutions developed with our pharma and veterinary customers’ needs in mind, aimed at enabling them to bring their drugs to market quickly and safely. This commitment to innovation is reflected by our dedication to sustainability, which is an integral component of our company strategy.
“As we support the UN Global Compact for the fifth consecutive year, we are particularly proud of our progress in reducing carbon emissions at our global glass manufacturing sites. SGD Pharma’s renewable energy initiatives, including the upgrade of our furnace at Saint Quentin Lamotte (SQLM) in France and the installation of solar panels at our Vemula, India plant, underscore an overarching focus on decarbonization with the company-wide goal to cut emissions recorded in 2020, by 35% by 2030 and by 65% by 2040. These efforts reflect our responsibility to our customers, partners and the planet as we strive for a safer and healthier environment.”
The introduction of RTU Type II vials aims to offer pharmaceutical companies more flexibility and faster time-to-market, while reducing overall production costs. Initially available in a 10ml size, the Type II vials will soon expand to additional sizes by 2025.
Sustainability is a key theme for SGD Pharma at this year’s CPHI. The company continues to invest in reducing its carbon footprint, aligning with its commitment to decarbonization. With goals to cut emissions by 35% by 2030 and by 65% by 2040.
In addition, SGD Pharma will showcase an extended product lineup. The IDENCY range, now available in 20ml and 6ml sizes, combines the benefits of moulded and tubular glass technologies for parenteral drugs, particularly those that are sensitive. The company’s Ensiemo line of syrup bottles will also feature new caps designed for tamper-evident and child-resistant closures.
SGD Pharma is expanding its LabServices offerings, which provide analytical testing support for pharmaceutical and biopharma companies, along with CMO/CDMOs and other glass manufacturers. Visitors can learn more about these services and the full product range at booth 20B11.
